Navigation Links
Experimental Drug Shows Promise Against Type 2 Diabetes
Date:2/27/2012

ey write that they are "excited about the potential of TAK-875 and are eager to conduct larger trials to find out how well this drug works, how safe it is and what its place is in the treatment of diabetes."

In a journal commentary, Clifford Bailey of Aston University in Birmingham, England, cautioned that, "on the journey to approval of a new class of treatment for type 2 diabetes, many questions will be asked of [drugs such as TAK-875]," including questions of how long they might remain effective, as well as safety issues.

Other diabetes experts had mixed views on the new findings.

Dr. Loren Wissner Greene is clinical associate professor of endocrinology at NYU Langone Medical Center in New York City. She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (Avandia was recently withdrawn from the U.S. market due to heart risks).

As for TAK-875, it targets a separate mechanism "but again, until more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism," Wissner Greene said.

Dr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, "given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents."

She said that, "though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain. However, like Wissner-Greene, Sood said that "further investigation is warranted, especially including [heart disease] patients."

More
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. First-in-human drug for malignant glioma available in experimental trial
2. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
3. Experimental Drugs Do Battle Against Advanced Prostate Cancer
4. Experimental Blood Thinner Given Before Surgery Shows Benefit
5. Wolfson Foundation awards £20 million to UCL for experimental neurology center
6. Novel experimental agent is highly active in CLL patients, interim study shows
7. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
8. Experimental Drug Slims Obese Monkeys
9. Experimental Psoriasis Drug Bests Older Treatment
10. Experimental Vaccine Shows Promise for Lung Cancer: Study
11. Experimental vaccine protects monkeys from blinding trachoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Shows Promise Against Type 2 Diabetes
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and ... neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor ... to earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was ... for a good cause. In its second year, the “Music With A Mission” benefit ... Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to help ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... evaluations for those seeking to go deep sea diving. The act of ... and decompression sickness; for these reasons, it is vital that all recreational and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan ... general use any time soon, according to educational website Surviving Mesothelioma. Click here ... orphan drug designation for mesothelioma last week from the FDA, will now head into ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... VSCP ), a leading provider of quantitative ... exceeds $27 million,compared to $14.7 million at the same ... company calculates backlog as the amount remaining to be,recognized ... studies,included within the backlog ranges from 2 months to ...
... nationally recognized Consumer Watchdog sent a letter today to ... to make health care affordable and available by allowing ... group warned Obama that a proposal pushed by health ... health insurance policies "amounts only to a government-funded customer ...
... Costs as Key , , WASHINGTON, ... Excellence report looks at how states are balancing retiree health care ... , Retiree Health Care in the American States ... care benefits to central human resources (HR) goals; how the states ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... is scheduled to speak at the Piper Jaffray Healthcare Conference ... Quest Diagnostics presentation is scheduled to begin at 4:00 p.m. ... During the conference, the company will reaffirm its 2008 ...
... Patients treated with radiation prior to surgery for ... and better overall survival rates, according to a recent ... neoadjuvant therapy, which can reduce cancerous tumor size or ... the tumor. Neoadjuvant therapy may include chemotherapy and/or radiation. ...
... probably higher with aprotinin, a drug commonly used to control ... analogues, according to a study http://www.cmaj.ca//cgi/rapidpdf/cmaj.081109 to be ... , On December 3, a Health Canada expert advisory ... is being early released in advance of the meeting. ...
Cached Medicine News:Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:States View Limits on Retiree Health Benefits 2Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... Lilly and Company (NYSE: LLY ) will attend ... 17, 2015. Sue Mahony , Ph.D., senior vice ... Gaynor , M.D., senior vice president of product development ... a fireside chat at 3:30 p.m., Eastern Daylight Time. ... available on the "Webcasts & Presentations" section of Lilly,s ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Be Useful in Cancer Treatment,Decisions , SALT LAKE ... (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today that,it presented ... used to,determine the original location of a metastatic ... meeting of the American Association,for Cancer Research (AACR) ...
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
Cached Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2
... automated, wireless, computerized remote temperature monitoring, ... refrigerator, freezer, incubator and water bath ... and manual temperature log reports., The ... and comes complete with installation, training ...
... water for use, it provides ... physically clean hands when routine ... an option or is not ... return to patient care faster, ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
Medicine Products: